The Journal of Clinical Psychiatry | JCP
@psychiatristcns.bsky.social
For clinicians, researchers, and mental health professionals shaping the future of psychiatry. From The Journal of Clinical Psychiatry.
🔍 In the premiere episode of The JCP Podcast, we dive into the world of mental-health research and publishing with JCP's Editor in Chief, Marlene Freeman, MD.
🎧 Available now on Spotify and Apple Podcasts, don’t miss it!
🔗 Spotify: https://bit.ly/43DbKPR
🔗 Apple: https://apple.co/3Jmk5Ax
🎧 Available now on Spotify and Apple Podcasts, don’t miss it!
🔗 Spotify: https://bit.ly/43DbKPR
🔗 Apple: https://apple.co/3Jmk5Ax
November 12, 2025 at 5:32 PM
🔍 In the premiere episode of The JCP Podcast, we dive into the world of mental-health research and publishing with JCP's Editor in Chief, Marlene Freeman, MD.
🎧 Available now on Spotify and Apple Podcasts, don’t miss it!
🔗 Spotify: https://bit.ly/43DbKPR
🔗 Apple: https://apple.co/3Jmk5Ax
🎧 Available now on Spotify and Apple Podcasts, don’t miss it!
🔗 Spotify: https://bit.ly/43DbKPR
🔗 Apple: https://apple.co/3Jmk5Ax
🔍 In the premiere episode of The JCP Podcast, we dive into the world of mental-health research and publishing with JCP's Editor in Chief, Marlene Freeman, MD.
🎧 Available now on Spotify and Apple Podcasts, don’t miss it!
🔗 Spotify: https://bit.ly/43DbKPR
🔗 Apple: https://apple.co/3Jmk5Ax
🎧 Available now on Spotify and Apple Podcasts, don’t miss it!
🔗 Spotify: https://bit.ly/43DbKPR
🔗 Apple: https://apple.co/3Jmk5Ax
November 10, 2025 at 12:32 PM
🔍 In the premiere episode of The JCP Podcast, we dive into the world of mental-health research and publishing with JCP's Editor in Chief, Marlene Freeman, MD.
🎧 Available now on Spotify and Apple Podcasts, don’t miss it!
🔗 Spotify: https://bit.ly/43DbKPR
🔗 Apple: https://apple.co/3Jmk5Ax
🎧 Available now on Spotify and Apple Podcasts, don’t miss it!
🔗 Spotify: https://bit.ly/43DbKPR
🔗 Apple: https://apple.co/3Jmk5Ax
🔍 In the premiere episode of The JCP Podcast, we dive into the world of mental-health research and publishing with JCP's Editor in Chief, Marlene Freeman, MD.
🎧 Available now on Spotify and Apple Podcasts, don’t miss it!
🔗 Spotify: https://bit.ly/43DbKPR
🔗 Apple: https://apple.co/3Jmk5Ax
🎧 Available now on Spotify and Apple Podcasts, don’t miss it!
🔗 Spotify: https://bit.ly/43DbKPR
🔗 Apple: https://apple.co/3Jmk5Ax
November 8, 2025 at 1:32 PM
🔍 In the premiere episode of The JCP Podcast, we dive into the world of mental-health research and publishing with JCP's Editor in Chief, Marlene Freeman, MD.
🎧 Available now on Spotify and Apple Podcasts, don’t miss it!
🔗 Spotify: https://bit.ly/43DbKPR
🔗 Apple: https://apple.co/3Jmk5Ax
🎧 Available now on Spotify and Apple Podcasts, don’t miss it!
🔗 Spotify: https://bit.ly/43DbKPR
🔗 Apple: https://apple.co/3Jmk5Ax
🔍 In the premiere episode of The JCP Podcast, we dive into the world of mental-health research and publishing with JCP's Editor in Chief, Marlene Freeman, MD.
🎧 Available now on Spotify and Apple Podcasts, don’t miss it!
🔗 Spotify: https://bit.ly/43DbKPR
🔗 Apple: https://apple.co/3Jmk5Ax
🎧 Available now on Spotify and Apple Podcasts, don’t miss it!
🔗 Spotify: https://bit.ly/43DbKPR
🔗 Apple: https://apple.co/3Jmk5Ax
November 6, 2025 at 9:32 PM
🔍 In the premiere episode of The JCP Podcast, we dive into the world of mental-health research and publishing with JCP's Editor in Chief, Marlene Freeman, MD.
🎧 Available now on Spotify and Apple Podcasts, don’t miss it!
🔗 Spotify: https://bit.ly/43DbKPR
🔗 Apple: https://apple.co/3Jmk5Ax
🎧 Available now on Spotify and Apple Podcasts, don’t miss it!
🔗 Spotify: https://bit.ly/43DbKPR
🔗 Apple: https://apple.co/3Jmk5Ax
Quality of life in FA isn’t just about walking or speech—it’s also about mood, behavior and functional participation. Our care models must keep up. Read more: https://bit.ly/3J6JKgp
#PatientCare #RareNeurologicDisorders
#PatientCare #RareNeurologicDisorders
Neuropsychiatric Challenges of Friedreich Ataxia in a Patient Residing in a Long-Term Care Facility
Management of behavioral symptoms in Friedreich’s ataxia patients requires a nuanced approach that integrates psychiatric care with traditional neurological treatment.
bit.ly
October 31, 2025 at 4:29 PM
Quality of life in FA isn’t just about walking or speech—it’s also about mood, behavior and functional participation. Our care models must keep up. Read more: https://bit.ly/3J6JKgp
#PatientCare #RareNeurologicDisorders
#PatientCare #RareNeurologicDisorders
For clinicians: seeing “AI counseling” as a tool, not a substitute. Ensure human supervision, cultural competence checks, and built-in crisis safeguards before deployment. Read more: https://bit.ly/49jjERN
#ClinicalPractice #TechIntegration
#ClinicalPractice #TechIntegration
AI Counselors Cross Ethical Lines
A new study warns that AI “therapy chatbots” often violate core ethical standards, raising questions about their safety and accountability.
bit.ly
October 31, 2025 at 3:50 PM
For clinicians: seeing “AI counseling” as a tool, not a substitute. Ensure human supervision, cultural competence checks, and built-in crisis safeguards before deployment. Read more: https://bit.ly/49jjERN
#ClinicalPractice #TechIntegration
#ClinicalPractice #TechIntegration
For mental-health program leaders: the evidence base for aripiprazole monohydrate LAI is maturing—now is a good time to revisit your protocols for selecting, initiating and following patients on LAIs. Read more: https://bit.ly/3JhyIoC 
#ServiceDesign #PsychiatricCare
#ServiceDesign #PsychiatricCare
Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report
A consensus panel reviews the pharmacokinetic advantages and clinical utility of long-acting injectable aripiprazole monohydrate to optimize treatment for schizophrenia and bipolar I disorder.
bit.ly
October 31, 2025 at 3:50 PM
For mental-health program leaders: the evidence base for aripiprazole monohydrate LAI is maturing—now is a good time to revisit your protocols for selecting, initiating and following patients on LAIs. Read more: https://bit.ly/3JhyIoC 
#ServiceDesign #PsychiatricCare
#ServiceDesign #PsychiatricCare
The research agenda must evolve: Which patient subgroups, treatment settings or infusion regimens might still show benefit? And how should outcomes be tracked over time? Read more: https://bit.ly/4qvn7To  #Research #InnovationInCare
Serial Ketamine Infusions Fail to Outperform Placebo in New Trial
A new clinical trial found that repeated ketamine infusions offered no meaningful advantage over an active placebo for depression patients.
bit.ly
October 31, 2025 at 3:27 PM
The research agenda must evolve: Which patient subgroups, treatment settings or infusion regimens might still show benefit? And how should outcomes be tracked over time? Read more: https://bit.ly/4qvn7To  #Research #InnovationInCare
Clinicians: when cognitive decline shows up, don’t only check hypertension. Ask: “Has the patient’s blood pressure dropped below their norm lately?” It could be a key clue. Read more: https://bit.ly/4hEktH5
#PatientCare #Assessment
#PatientCare #Assessment
The Impact of Relative and Absolute Hypotension on Cognitive Function
Hypotension acts synergistically to affect mental status by compounding problems with gas exchange, neurovascular dynamics, neuronal metabolism, and neurotoxicity.
bit.ly
October 31, 2025 at 1:09 PM
Clinicians: when cognitive decline shows up, don’t only check hypertension. Ask: “Has the patient’s blood pressure dropped below their norm lately?” It could be a key clue. Read more: https://bit.ly/4hEktH5
#PatientCare #Assessment
#PatientCare #Assessment
The brain’s “fuel” is blood flow. Cut it off (even partially) and you trigger oxidative stress, calcium influx, cell death—starting within minutes. 
https://bit.ly/4hEktH5
#PerfusionMatters #Neurobiology
https://bit.ly/4hEktH5
#PerfusionMatters #Neurobiology
The Impact of Relative and Absolute Hypotension on Cognitive Function
Hypotension acts synergistically to affect mental status by compounding problems with gas exchange, neurovascular dynamics, neuronal metabolism, and neurotoxicity.
www.psychiatrist.com
October 31, 2025 at 1:19 AM
The brain’s “fuel” is blood flow. Cut it off (even partially) and you trigger oxidative stress, calcium influx, cell death—starting within minutes. 
https://bit.ly/4hEktH5
#PerfusionMatters #Neurobiology
https://bit.ly/4hEktH5
#PerfusionMatters #Neurobiology
Accountability gap: Unlike licensed human therapists, AI counselors are not certified, regulated or bound by professional boards — yet they’re engaging in therapeutic roles. That matters. Read more: https://bit.ly/49jjERN
#Regulation #AIInHealth
#Regulation #AIInHealth
AI Counselors Cross Ethical Lines
A new study warns that AI “therapy chatbots” often violate core ethical standards, raising questions about their safety and accountability.
bit.ly
October 30, 2025 at 3:55 PM
Accountability gap: Unlike licensed human therapists, AI counselors are not certified, regulated or bound by professional boards — yet they’re engaging in therapeutic roles. That matters. Read more: https://bit.ly/49jjERN
#Regulation #AIInHealth
#Regulation #AIInHealth
Interdisciplinary coordination (neurology + psychiatry + long-term-care nursing) is not optional—it’s essential when behavioral symptoms emerge in hereditary ataxia settings. Read more: https://bit.ly/3J6JKgp
#LongTermCare #TeamBasedCare
#LongTermCare #TeamBasedCare
Neuropsychiatric Challenges of Friedreich Ataxia in a Patient Residing in a Long-Term Care Facility
Management of behavioral symptoms in Friedreich’s ataxia patients requires a nuanced approach that integrates psychiatric care with traditional neurological treatment.
bit.ly
October 30, 2025 at 3:02 PM
Interdisciplinary coordination (neurology + psychiatry + long-term-care nursing) is not optional—it’s essential when behavioral symptoms emerge in hereditary ataxia settings. Read more: https://bit.ly/3J6JKgp
#LongTermCare #TeamBasedCare
#LongTermCare #TeamBasedCare
Embedding LAIs into treatment workflows: beyond prescribing, services must include patient education, monitoring intervals and adherence support to fully leverage the advantages of aripiprazole LAI. Read more: https://bit.ly/3JhyIoC
#MentalHealthServices #Implementation
#MentalHealthServices #Implementation
Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report
A consensus panel reviews the pharmacokinetic advantages and clinical utility of long-acting injectable aripiprazole monohydrate to optimize treatment for schizophrenia and bipolar I disorder.
bit.ly
October 30, 2025 at 3:02 PM
Embedding LAIs into treatment workflows: beyond prescribing, services must include patient education, monitoring intervals and adherence support to fully leverage the advantages of aripiprazole LAI. Read more: https://bit.ly/3JhyIoC
#MentalHealthServices #Implementation
#MentalHealthServices #Implementation
For programs offering off-label ketamine infusions: current evidence suggests modest benefit at best when used as an adjunct in inpatient settings. Managing expectations is essential. Read more: https://bit.ly/4qvn7To  #HealthServices #PatientCare
Serial Ketamine Infusions Fail to Outperform Placebo in New Trial
A new clinical trial found that repeated ketamine infusions offered no meaningful advantage over an active placebo for depression patients.
bit.ly
October 30, 2025 at 2:42 PM
For programs offering off-label ketamine infusions: current evidence suggests modest benefit at best when used as an adjunct in inpatient settings. Managing expectations is essential. Read more: https://bit.ly/4qvn7To  #HealthServices #PatientCare
Hypotension + another insult (hypoxia, anemia, TBI) = higher risk for cognitive/neurological damage. It’s the combo that compounds the harm. 
https://bit.ly/4hEktH5
#CriticalCare #BrainFlow
https://bit.ly/4hEktH5
#CriticalCare #BrainFlow
The Impact of Relative and Absolute Hypotension on Cognitive Function
Hypotension acts synergistically to affect mental status by compounding problems with gas exchange, neurovascular dynamics, neuronal metabolism, and neurotoxicity.
bit.ly
October 29, 2025 at 11:20 PM
Hypotension + another insult (hypoxia, anemia, TBI) = higher risk for cognitive/neurological damage. It’s the combo that compounds the harm. 
https://bit.ly/4hEktH5
#CriticalCare #BrainFlow
https://bit.ly/4hEktH5
#CriticalCare #BrainFlow
A new inpatient trial of repeated ketamine infusions found no significant advantage over an active psychoactive control in reducing depressive symptoms. Read more: https://bit.ly/4qvn7To  #Psychiatry #Depression
Serial Ketamine Infusions Fail to Outperform Placebo in New Trial
A new clinical trial found that repeated ketamine infusions offered no meaningful advantage over an active placebo for depression patients.
bit.ly
October 29, 2025 at 8:46 PM
A new inpatient trial of repeated ketamine infusions found no significant advantage over an active psychoactive control in reducing depressive symptoms. Read more: https://bit.ly/4qvn7To  #Psychiatry #Depression
The pharmacologic balance in FA: Treating psychiatric symptoms without worsening motor/neurologic function is complex—but possible, as shown in a recent long-term care case. Read more: https://bit.ly/3J6JKgp
#Psychopharmacology #Neurology
#Psychopharmacology #Neurology
Neuropsychiatric Challenges of Friedreich Ataxia in a Patient Residing in a Long-Term Care Facility
Management of behavioral symptoms in Friedreich’s ataxia patients requires a nuanced approach that integrates psychiatric care with traditional neurological treatment.
bit.ly
October 29, 2025 at 8:30 PM
The pharmacologic balance in FA: Treating psychiatric symptoms without worsening motor/neurologic function is complex—but possible, as shown in a recent long-term care case. Read more: https://bit.ly/3J6JKgp
#Psychopharmacology #Neurology
#Psychopharmacology #Neurology
Initiation planning matters: variability in metabolism (CYP2D6/CYP3A4), drug-interactions and patient history must guide LAI selection and management. Read more: https://bit.ly/3JhyIoC
#ClinicalPractice #PrecisionMedicine
#ClinicalPractice #PrecisionMedicine
Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report
A consensus panel reviews the pharmacokinetic advantages and clinical utility of long-acting injectable aripiprazole monohydrate to optimize treatment for schizophrenia and bipolar I disorder.
bit.ly
October 29, 2025 at 5:17 PM
Initiation planning matters: variability in metabolism (CYP2D6/CYP3A4), drug-interactions and patient history must guide LAI selection and management. Read more: https://bit.ly/3JhyIoC
#ClinicalPractice #PrecisionMedicine
#ClinicalPractice #PrecisionMedicine
One hour. Two experts. 1.25 CME credits.
All designed to help you deliver better DMD care.
🗓 October 30 | Live Virtual CME
🔗 Register → https://cmeinstitute.com/live-dmd-2025/
All designed to help you deliver better DMD care.
🗓 October 30 | Live Virtual CME
🔗 Register → https://cmeinstitute.com/live-dmd-2025/
Live CME Activity Series on Next-Generation DMD Care
CME Institute | Innovative and Accredited CME for Today’s Practicing Clinicians
cmeinstitute.com
October 29, 2025 at 3:46 PM
One hour. Two experts. 1.25 CME credits.
All designed to help you deliver better DMD care.
🗓 October 30 | Live Virtual CME
🔗 Register → https://cmeinstitute.com/live-dmd-2025/
All designed to help you deliver better DMD care.
🗓 October 30 | Live Virtual CME
🔗 Register → https://cmeinstitute.com/live-dmd-2025/
Crisis-handling matters: Chatbots that don’t reliably offer emergency resources when suicidal ideation arises are operating outside the ethics we expect in therapy. Read more: https://bit.ly/49jjERN 
#PatientSafety #AIMentalHealth
#PatientSafety #AIMentalHealth
AI Counselors Cross Ethical Lines
A new study warns that AI “therapy chatbots” often violate core ethical standards, raising questions about their safety and accountability.
bit.ly
October 29, 2025 at 7:09 AM
Crisis-handling matters: Chatbots that don’t reliably offer emergency resources when suicidal ideation arises are operating outside the ethics we expect in therapy. Read more: https://bit.ly/49jjERN 
#PatientSafety #AIMentalHealth
#PatientSafety #AIMentalHealth
When you hear “low blood pressure,” think: is this low *for this patient? A drop from their baseline may hurt cognition even if it’s within “normal” range for most. 
Read more: https://bit.ly/4hEktH5
#ClinicalInsight #Neurology
Read more: https://bit.ly/4hEktH5
#ClinicalInsight #Neurology
The Impact of Relative and Absolute Hypotension on Cognitive Function
Hypotension acts synergistically to affect mental status by compounding problems with gas exchange, neurovascular dynamics, neuronal metabolism, and neurotoxicity.
bit.ly
October 28, 2025 at 9:08 PM
When you hear “low blood pressure,” think: is this low *for this patient? A drop from their baseline may hurt cognition even if it’s within “normal” range for most. 
Read more: https://bit.ly/4hEktH5
#ClinicalInsight #Neurology
Read more: https://bit.ly/4hEktH5
#ClinicalInsight #Neurology
More than generative text: When AI “counselors” overlook cultural/familial context (e.g., advising independence while ignoring guilt tied to cultural norms) — that’s a red flag. Read more: https://bit.ly/49jjERN
#DigitalTherapy #ClinicalInsight
#DigitalTherapy #ClinicalInsight
AI Counselors Cross Ethical Lines
A new study warns that AI “therapy chatbots” often violate core ethical standards, raising questions about their safety and accountability.
bit.ly
October 28, 2025 at 8:53 PM
More than generative text: When AI “counselors” overlook cultural/familial context (e.g., advising independence while ignoring guilt tied to cultural norms) — that’s a red flag. Read more: https://bit.ly/49jjERN
#DigitalTherapy #ClinicalInsight
#DigitalTherapy #ClinicalInsight
In FA, neuropsychiatric symptoms are under-recognized as part of the disease spectrum. Early detection and integrated care can make a major difference. Read more: https://bit.ly/3J6JKgp
#RareDisease #BehavioralHealth
#RareDisease #BehavioralHealth
Neuropsychiatric Challenges of Friedreich Ataxia in a Patient Residing in a Long-Term Care Facility
Management of behavioral symptoms in Friedreich’s ataxia patients requires a nuanced approach that integrates psychiatric care with traditional neurological treatment.
www.psychiatrist.com
October 28, 2025 at 3:40 PM
In FA, neuropsychiatric symptoms are under-recognized as part of the disease spectrum. Early detection and integrated care can make a major difference. Read more: https://bit.ly/3J6JKgp
#RareDisease #BehavioralHealth
#RareDisease #BehavioralHealth
The once-every-two-month ready-to-use aripiprazole LAI is now emphasized for its potential to improve convenience and adherence—especially in populations where daily medication is challenging. Read more: https://bit.ly/3JhyIoC
#Adherence #Psychopharmacology
#Adherence #Psychopharmacology
Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report
A consensus panel reviews the pharmacokinetic advantages and clinical utility of long-acting injectable aripiprazole monohydrate to optimize treatment for schizophrenia and bipolar I disorder.
bit.ly
October 28, 2025 at 3:40 PM
The once-every-two-month ready-to-use aripiprazole LAI is now emphasized for its potential to improve convenience and adherence—especially in populations where daily medication is challenging. Read more: https://bit.ly/3JhyIoC
#Adherence #Psychopharmacology
#Adherence #Psychopharmacology
Blinding issues matter: in the trial most participants and raters accurately guessed who received ketamine — a factor that may inflate perceived benefits.  Read more: https://bit.ly/4qvn7To
#ClinicalTrialDesign #Psychopharmacology
#ClinicalTrialDesign #Psychopharmacology
Serial Ketamine Infusions Fail to Outperform Placebo in New Trial
A new clinical trial found that repeated ketamine infusions offered no meaningful advantage over an active placebo for depression patients.
bit.ly
October 28, 2025 at 3:15 PM
Blinding issues matter: in the trial most participants and raters accurately guessed who received ketamine — a factor that may inflate perceived benefits.  Read more: https://bit.ly/4qvn7To
#ClinicalTrialDesign #Psychopharmacology
#ClinicalTrialDesign #Psychopharmacology